Lysine demethylase 5B (KDM5B): A key regulator of cancer drug resistance

J Biochem Mol Toxicol. 2024 Jan;38(1):e23587. doi: 10.1002/jbt.23587. Epub 2023 Nov 28.

Abstract

Chemoresistance, a roadblock in the chemotherapy process, has been impeding its effective treatment. KDM5B, a member of the histone demethylase family, has been crucial in the emergence and growth of malignancies. More significantly, KDM5B has recently been linked closely to cancer's resistance to chemotherapy. In this review, we explain the biological properties of KDM5B, its function in the emergence and evolution of cancer treatment resistance, and our hopes for future drug resistance-busting combinations involving KDM5B and related targets or medications.

Keywords: KDM5B; chemoresistance; combination therapy; tumor.

Publication types

  • Review

MeSH terms

  • Drug Resistance, Neoplasm
  • Humans
  • Jumonji Domain-Containing Histone Demethylases
  • Lysine*
  • Neoplasms* / drug therapy
  • Nuclear Proteins
  • Repressor Proteins

Substances

  • Lysine
  • KDM5B protein, human
  • Nuclear Proteins
  • Repressor Proteins
  • Jumonji Domain-Containing Histone Demethylases